Aptevo Therapeutics Completes Separation from Emergent BioSolutions
“Today is the culmination of the hard work of our entire team at Aptevo,
and marks a major milestone for our company,” said
Under the terms of the separation, Emergent stockholders of record as of
the close of business on
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding the benefits of the separation transaction to Aptevo, Aptevo’s technology and related pipeline, collaboration and partnership opportunities and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo’s actual
results to differ materially from those indicated by such
forward-looking statements, including possible negative effects on
Aptevo’s business operations, assets or financial results as a result of
the separation; a deterioration in the business or prospects of Aptevo;
adverse developments in Aptevo’s customer-base or markets; adverse
developments in the U.S. or global capital markets, credit markets or
economies generally; and changes in regulatory, social and political
conditions. Additional risks and factors that may affect results are set
forth in Aptevo’s filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005403/en/
Source:
Aptevo Therapeutics
Stacey Jurchison, 206-859-6628
Senior
Director, Investor Relations and Corporate Communications
JurchisonS@apvo.com